Goodwin Procter LLP advised Cullinan Management, Inc. on the deal.
Cullinan announced its oversubscribed $131.2 million Series C financing. The financing was led by Foresite Capital with participation from additional new investors: Boxer Capital of Tavistock Group; Eventide Asset Management; Nextech Invest; OrbiMed; Venrock Healthcare Capital Partners; Rock Springs Capital; BVF Partners, L.P.; and Logos Capital. Existing investors, including MPM Capital, F2 Ventures, Cowen Healthcare Investments, The Baupost Group, Schooner Capital, as well as other institutions and individuals, also participated in the round.
Cullinan is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
The Goodwin team handling the Series C financing was led by Mitch Bloom (Picture), Danielle Lauzon, Gabriela Morales-Rivera, Katherine Hand, and Owen Remeika, and included Dan Karelitz and Mark Burnett with invaluable assistance from Pat Robichaud.
Involved fees earner: Mitchell Bloom – Goodwin Procter; Mark Burnett – Goodwin Procter; Katherine Hand – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Danielle Lauzon – Goodwin Procter; Gabriela Morales-Rivera – Goodwin Procter;
Law Firms: Goodwin Procter;
Clients: Cullinan Management;